- Revolution Medicines Inc RVMD announced that Sanofi SA SNY has terminated global SHP2 development and commercialization collaboration.
- Following termination, Revolution Medicines will regain all global rights granted to Sanofi under the agreement, including decision-making regarding R&D and rights to all commercial proceeds from RMC-4630, an SHP2 inhibitor drug candidate in development for certain RAS-addicted cancers.
- The companies plan to collaborate to transition Sanofi's rights and obligations related to RMC-4630 back to Revolution Medicines over the first half of 2023.
- Revolution Medicines is enrolling patients in its global Phase 2 RMC-4630-03 trial assessing RMC-4630 in combination with Amgen Inc's AMGN Lumakras (sotorasib) in non-small cell lung cancer harboring KRASG12C mutation.
- The company expects to provide topline data from this study in the second half of 2023.
- With current cash, cash equivalents, and marketable securities, Revolution Medicines expects that it can fund planned operations through 2024.
- The company is updating its projected FY22 2022 GAAP net loss of $(245)-$(265) million versus $(260)-$(280) million expected previously.
- Price Action: RVMD shares closed lower by 1.43% at $24.15 on Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.